行情

EXAS

EXAS

精密科学
NASDAQ

实时行情|Nasdaq Last Sale

108.15
+5.36
+5.21%
盘后: 106.06 -2.09 -1.93% 19:29 09/17 EDT
开盘
102.34
昨收
102.79
最高
108.99
最低
101.22
成交量
249.86万
成交额
--
52周最高
159.54
52周最低
70.75
市值
185.96亿
市盈率(TTM)
-19.7657
分时
5日
1月
3月
1年
5年
思科股票应该会从即将到来的设备购买浪潮中获得提振
The company’s best customers are likely to step up their spending. Also, Wall Street views on Electronic Arts, Exact Sciences, Albireo Pharma, Regions Financial, and Papa John’s International.
Barrons.com · 20小时前
为什么 Exact Sciences 的股票今天交易更高
Exact Sciences (NASDAQ:EXAS) shares are trading higher after the company announced an expansion of its primary care sales team with the addition of former Pfizer sales representatives.
Benzinga · 3天前
分析师表示,由于辉瑞销售协议的变化是“积极的”,确切的股票飙升
Shares of Exact Sciences Corp. rallied 8.0% in afternoon trading Wednesday, after the molecular diagnostics company said it taking over the selling of its Cologuard at-home colon cancer screening test from Pfizer Inc. , and said it was discussing with Pfiz...
Marketwatch.com · 3天前
Brief-Exact Sciences 正在与辉瑞进行讨论,这可能导致促销协议、与辉瑞的关系发生重大变化
reuters.com · 3天前
Exact Sciences 8-K Shows Co. 扩大其初级保健销售团队,以增加对 Cologuard 的采用,其癌症筛查测试管道
On September 15, 2021, Exact Sciences Corporation (“Exact Sciences”) announced it has expanded its primary care sales team to increase adoption of Cologuard®, the first and only FDA-approved, at-home
Benzinga · 3天前
BRIEF-Exact Sciences Announces Clinical Validation Study To Detect Minimal Residual Cancer
reuters.com · 4天前
Exact Sciences 和国家外科辅助乳房和肠道项目宣布临床验证研究,以检测结直肠癌患者的最小残留疾病
Exact Sciences Corp. (NASDAQ: EXAS) announced today that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a cooperative group founded by the National Cancer Institute (NCI).
Benzinga · 4天前
未来十年最值得购买的 10 只股票
In this article, we will examine the reasons why Cathie Wood is sticking to her innovation-centric strategy despite lower than expected performance in the first half of 2021. We will also review the 10 best stocks to buy for the next ten years based on Cat...
Insider Monkey · 09/07 16:55
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解EXAS最新的财务预测,通过EXAS每股收益,每股净资产,每股现金流等数据分析精密科学近期的经营情况,然后做出明智的投资选择。
分析师评级

18位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测EXAS价格均价为148.88,最高价位165.00,最低价为120.00。
EPS
机构持股
总机构数: 835
机构持股: 1.71亿
持股比例: 99.23%
总股本: 1.72亿
类型机构数股数
增持
276
1,061.97万
建仓
65
240.88万
减持
141
858.61万
平仓
85
174.46万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.49%
制药与医学研究
-0.10%
高管信息
Chairman/President/Chief Executive Officer/Director
Kevin Conroy
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Jeffrey Elliott
Senior Vice President/Chief Administrative Officer/General Counsel/Secretary
D. Scott Coward
Senior Vice President
Ana Hooker
Chief Scientific Officer
Graham Lidgard
General Manager
Jake Orville
General Manager
Gisela Paulsen
Independent Director
James Doyle
Independent Director
Pierre Jacquet
Independent Director
Daniel Levangie
Independent Director
Freda Lewis-Hall
Independent Director
Shacey Petrovic
Independent Director
Kathleen Sebelius
Independent Director
Katherine Zanotti
暂无数据
EXAS 简况
Exact Sciences Corporation是一家癌症筛查和诊断公司。该公司专注于早期检测和预防某些类型的癌症。该公司提供了一种称为Cologuard的非侵入性筛查测试,可用于大肠癌、癌前期和Oncotype DX的早期检测。Cologuard测试是一种基于粪便的脱氧核糖核酸(sDNA)筛选测试,利用多目标方法来检测与大肠癌和癌前期相关的脱氧核糖核酸(DNA)和血红蛋白生物标志物。Cologuard测试旨在定性检测结直肠瘤形成相关的DNA标记,并检测人类粪便中是否存在隐匿性血红蛋白。该公司专注于开发其他类型癌症的附加测试,该公司正在开发一种基于血液的生物标志物测试,通过计算机断层扫描(CT)或其他扫描发现的患有肺结节的个体来协助肺癌早期诊断。

微牛提供EXACT Sciences Corporation(NASDAQ-EXAS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的EXAS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易EXAS股票基本功能。